Scancell Holdings Plc Scancell to present three posters at ICI (3786M)
September 14 2023 - 2:00AM
UK Regulatory
TIDMSCLP
RNS Number : 3786M
Scancell Holdings Plc
14 September 2023
14 September 2023
Scancell Holdings plc
("Scancell" or the "Company")
Scancell to present three posters at the Seventh International
Cancer Immunotherapy Conference
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
announces it will present three posters at the Seventh
International Cancer Immunotherapy Conference, jointly organised by
the American Association for Cancer Research, the European Network
for Cancer Immunotherapy and the Cancer Research Institute and
taking place on 20-23 September 2023 in Milan, Italy.
Prof Lindy Durrant, Chief Executive Officer and Chief Scientific
Officer of Scancell, commented: "We look forward to presenting at
such a prestigious meeting and sharing data on our preclinical
programmes with the scientific community. As previously disclosed
in a recent business update , we continue to make great progress in
the clinic with our two lead cancer vaccine assets SCIB1/iSCIB-1+
and Modi-1 currently in Phase 1/2 clinical trials as well as
leveraging the value of our antibody platform to generate revenue
through high value licence agreements.
"Showcasing the potential of our technology platforms to
generate further pipeline assets with high value partnering
opportunities, we will be presenting encouraging data on both the
Moditope(R) and GlyMab(R) platforms. Data on antibody candidates
derived from the GlyMab(R) platform illustrate the potential of
these assets as chimeric antigen receptor T cell (CAR-T) therapies
and could lead to out licensing opportunities with cell therapy
companies. Furthermore, we will be presenting data bolstering the
potential of Modi-2 as a solid tumour cancer therapy and further
characterising the response to Moditope(R) peptides in preclinical
studies."
The title, timing and location of the poster presentation are as
follows:
Poster 1
Poster presentation Anti-sialyl-di-lewisa CAR T cells for effective
title anti-tumour therapy
Authors Iniobong Charles, Katherine Cook, Bubacarr
Kaira, Gaëlle Cane, Anne Skinner, Alissa
Wright, Mireille Vankemmelbeke, Rachael Metheringham,
Victoria Brentville and Lindy Durrant
Session title Poster Session A
Session date and 12.30 - 14.00 CET, 21(st) September, 2023
time
Location Poster Board number P232
Poster 2
Poster presentation Vaccination stimulating post-translational
title modification specific Th1 responses repolarises
the tumour environment to reduce suppressive
LAP expressing T cells
Authors Suha Atabani, Katherine Cook, Peter Symonds,
Ian Daniels, Ruhul Choudhury, Alissa Wright,
Anne Skinner, Victoria Brentville and Lindy
Durrant
Session title Poster Session A
Session date and 12.30 - 14.00 CET, 21(st) September, 2023
time
Location Poster Board number P230
Poster 3
Poster presentation Modi-2, a vaccine targeting homocitrullinated
title self-epitopes, stimulates potent CD4-mediated
anti-tumour responses as a therapy for solid
cancers
Authors Abdullah Al-Omari, Katherine Cook, Peter Symonds,
Anne Skinner, Yaling Zhu, Vince Coble, Nazim
Uddin, Priscilla Ranglani, Adrian Parry, Sally
Adams, Geoffrey Lynn, Lindy Durrant and Victoria
Brentville
Session title Poster Session B
Session date and 12.45 - 14.00 CET, 22(nd) September, 2023
time
Location Poster Board number P217
Copies of the poster will be available on Scancell's website
following the conference at:
https://www.scancell.co.uk/vaccine-publications
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3727 1000
Dr Jean-Michel Cosséry, Non-Executive Chairman
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications Tel.: +44 (0) 20 3709 5700
Mary-Jane Elliott/Matthew Neal/Chris Welsh scancell@consilium-comms.com
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope (R) and
ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody
(R) ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab(R) ) or enhances
the potency of antibodies and their ability to directly kill tumour
cells (AvidiMab (R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFIFUDEDSEIU
(END) Dow Jones Newswires
September 14, 2023 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024